-
Zylox-Tonbridge Completes Patient Enrollment for ZENFLEX Study in Germany
•
Zylox-Tonbridge Medical Technology (HKG: 2190), a China-based developer of nerve and peripheral vascular interventional devices, has announced the completion of patient enrollment in a multi-center clinical study for its ZENFLEX peripheral vascular stent system in Germany. The study has reached its target of 100 patients. This prospective, multi-center, single-arm study…
-
Jiangsu Hengrui Medicine Wins NMPA Approvals for SLE and Lymphoma Drug Candidates
•
Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276), a leading Chinese pharmaceutical company, has announced that it has received separate clinical trial approvals from China’s National Medical Products Administration (NMPA) for two of its drug candidates, SHR0302 and SHR2554. SHR0302 is anticipated to treat systemic lupus erythematosus (SLE), while SHR2554 is…
-
RemeGen’s Telitacicept Secures FDA Approval for Global Phase III Study in Primary Sjogren’s Syndrome
•
RemeGen (HKG: 9995), a China-based pharmaceutical company, has received approval from the US Food and Drug Administration (FDA) to proceed with a global multi-center Phase III clinical study for its fusion protein drug telitacicept in the treatment of active primary Sjogren’s syndrome (pSS). This 48-week, multi-center, randomized, double-blinded, placebo-controlled Phase…
-
Novo Nordisk Foundation Launches $260 Million Initiative to Develop Respiratory Disease Vaccines
•
Novo Nordisk Foundation, the entity that controls Denmark-based Novo Nordisk (CPH: NOVO-B), has unveiled an ambitious new initiative to bolster immunizations against respiratory diseases with a DKK 1.8 billion (USD 260 million) investment. This project, named the Novo Nordisk Foundation Initiative for Vaccines and Immunity (NIVI), aims to develop or…
-
LianBio Board Turns Down Concentra Biosciences Buyout Offer
•
China-based LianBio (OTCMKTS: LIANY) has announced that its board of directors has unanimously decided not to proceed with a buyout proposal from Concentra Biosciences LLC, deeming the offer not to be in the best interests of shareholders. In early December, Concentra Biosciences LLC, a company under the control of private…
-
Gilead Acquires Pre-Clinical IL-18BP Targeting Antibody Candidate from Compugen in $848 Million Deal
•
Gilead (NASDAQ: GILD) has licensed a potential first-in-class IL-18 binding protein (IL-18BP) targeting antibody candidate from cancer immunotherapy developer Compugen (NASDAQ: CGEN), which is currently in the pre-clinical stage. Gilead will assume development responsibilities from Phase II onwards and will pay USD 60 million upfront, with up to USD 788…
-
Jiangsu Synthgene and Starna Therapeutics Join Forces in mRNA Technology Advancement
•
China’s Jiangsu Synthgene Biotechnology Co., Ltd has announced a strategic partnership with Suzhou-based Starna Therapeutics, an RNA drug developer. The collaboration will focus on mRNA raw materials, lipid chemistry, lipid nanoparticle (LNP) technology, and complex preparations, among other areas. Financial details of the agreement have not been disclosed. Synthgene and…
-
Shanghai Escugen Partners with InxMed for Global Development Rights to EZWi-Fit Platform
•
Shanghai Escugen has entered into a partnership with InxMed (Nanjing) Co., Ltd, granting the Chinese firm non-exclusive global rights to Escugen’s EZWi-Fit linker-payload platform for the development of next-generation tumor-associated antigen (TAA)-targeting antibody drug conjugates (ADCs). Under the terms of the license agreement, InxMed is authorized to utilize the EZWi-Fit…
